$BIOLQ
BIOLASE, INC

2022 Q4 Form 10-Q Financial Statement

#000095017022024532 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $14.05M $12.01M
YoY Change 13.24% 26.01%
Cost Of Revenue $10.46M $9.565M
YoY Change 39.36% 103.99%
Gross Profit $3.596M $2.445M
YoY Change -26.7% -49.5%
Gross Profit Margin 25.59% 20.36%
Selling, General & Admin $9.935M $8.117M
YoY Change 29.55% 36.88%
% of Gross Profit 276.28% 331.98%
Research & Development $2.088M $1.979M
YoY Change 35.41% 28.51%
% of Gross Profit 58.06% 80.94%
Depreciation & Amortization $128.0K $122.0K
YoY Change 7.56% 16.19%
% of Gross Profit 3.56% 4.99%
Operating Expenses $12.02M $10.10M
YoY Change 30.53% 34.63%
Operating Profit -$8.427M -$7.651M
YoY Change 95.75% 187.96%
Interest Expense -$1.348M -$424.0K
YoY Change 73.49% -174.52%
% of Operating Profit
Other Income/Expense, Net -$753.0K
YoY Change 24.46%
Pretax Income -$9.775M -$8.404M
YoY Change 87.73% 157.63%
Income Tax $86.00K -$17.00K
% Of Pretax Income
Net Earnings -$9.861M -$8.387M
YoY Change 86.8% 156.01%
Net Earnings / Revenue -70.18% -69.83%
Basic Earnings Per Share -$1.10
Diluted Earnings Per Share -$1.28 -$1.10
COMMON SHARES
Basic Shares Outstanding 7.146M 6.855M
Diluted Shares Outstanding 7.615M

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.181M $9.960M
YoY Change -86.05% -70.17%
Cash & Equivalents $4.181M $10.00M
Short-Term Investments
Other Short-Term Assets $1.166M $2.648M
YoY Change -12.46% 68.66%
Inventory $15.88M $16.43M
Prepaid Expenses
Receivables $5.800M $4.800M
Other Receivables $0.00 $0.00
Total Short-Term Assets $28.96M $33.88M
YoY Change -41.32% -35.65%
LONG-TERM ASSETS
Property, Plant & Equipment $4.278M $3.915M
YoY Change 300.94% 340.38%
Goodwill $2.926M $2.900M
YoY Change 0.9% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $255.0K $234.0K
YoY Change 15.91% 5.41%
Total Long-Term Assets $9.227M $8.984M
YoY Change 55.6% 53.31%
TOTAL ASSETS
Total Short-Term Assets $28.96M $33.88M
Total Long-Term Assets $9.227M $8.984M
Total Assets $38.19M $42.87M
YoY Change -30.93% -26.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.786M $4.974M
YoY Change 74.86% 38.28%
Accrued Expenses $9.210M $6.919M
YoY Change 11.29% 11.92%
Deferred Revenue $2.111M $1.870M
YoY Change -6.55% -17.91%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $700.0K $0.00
YoY Change -100.0%
Total Short-Term Liabilities $17.81M $13.76M
YoY Change 28.63% 2.27%
LONG-TERM LIABILITIES
Long-Term Debt $13.09M $12.79M
YoY Change -3.76% 5.61%
Other Long-Term Liabilities $362.0K $260.0K
YoY Change 9.7% -12.75%
Total Long-Term Liabilities $13.45M $13.05M
YoY Change -3.45% 5.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.81M $13.76M
Total Long-Term Liabilities $13.45M $13.05M
Total Liabilities $33.30M $29.01M
YoY Change 10.71% 2.89%
SHAREHOLDERS EQUITY
Retained Earnings -$296.2M -$286.3M
YoY Change 10.7% 9.17%
Common Stock $301.8M $301.2M
YoY Change 2.88% 2.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.889M $13.86M
YoY Change
Total Liabilities & Shareholders Equity $38.19M $42.87M
YoY Change -30.93% -26.74%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$9.861M -$8.387M
YoY Change 86.8% 156.01%
Depreciation, Depletion And Amortization $128.0K $122.0K
YoY Change 7.56% 16.19%
Cash From Operating Activities -$5.582M -$6.546M
YoY Change 79.83% 81.93%
INVESTING ACTIVITIES
Capital Expenditures $471.0K -$2.678M
YoY Change -251.45% 3050.59%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$471.0K -$2.678M
YoY Change 51.45% 3050.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -32.00K -214.0K
YoY Change -147.06% -385.33%
NET CHANGE
Cash From Operating Activities -5.582M -6.546M
Cash From Investing Activities -471.0K -2.678M
Cash From Financing Activities -32.00K -214.0K
Net Change In Cash -6.085M -9.438M
YoY Change 81.8% 161.59%
FREE CASH FLOW
Cash From Operating Activities -$5.582M -$6.546M
Capital Expenditures $471.0K -$2.678M
Free Cash Flow -$6.053M -$3.868M
YoY Change 116.72% 10.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
dei Entity Central Index Key
EntityCentralIndexKey
0000811240
biol Proceeds From Sale Of Common Stock Warrants
ProceedsFromSaleOfCommonStockWarrants
biol Principal Payment On Loan
PrincipalPaymentOnLoan
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36385
dei Entity Registrant Name
EntityRegistrantName
BIOLASE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0442441
dei Entity Address Address Line1
EntityAddressAddressLine1
27042 Towne Centre Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 270
dei Entity Address City Or Town
EntityAddressCityOrTown
Lake Forest
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92610
dei City Area Code
CityAreaCode
949
dei Local Phone Number
LocalPhoneNumber
361-1200
dei Security12b Title
Security12bTitle
Common stock at par value $0.001 per share
dei Trading Symbol
TradingSymbol
BIOL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7145529
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9960000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29972000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
0
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
203000
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2172000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2154000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4846000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4238000
CY2022Q3 us-gaap Inventory Net
InventoryNet
16427000
CY2021Q4 us-gaap Inventory Net
InventoryNet
12929000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2648000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2012000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
33881000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
49354000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3915000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1067000
CY2022Q3 us-gaap Goodwill
Goodwill
2926000
CY2021Q4 us-gaap Goodwill
Goodwill
2926000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1909000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1717000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
234000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
220000
CY2022Q3 us-gaap Assets
Assets
42865000
CY2021Q4 us-gaap Assets
Assets
55284000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4974000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3309000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6919000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8276000
CY2022Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1870000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2259000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
13763000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13844000
CY2022Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
347000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
329000
CY2022Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
416000
CY2021Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
521000
CY2022Q3 us-gaap Mediumterm Notes Noncurrent
MediumtermNotesNoncurrent
12793000
CY2021Q4 us-gaap Mediumterm Notes Noncurrent
MediumtermNotesNoncurrent
13603000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1428000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1449000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
260000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
330000
CY2022Q3 us-gaap Liabilities
Liabilities
29007000
CY2021Q4 us-gaap Liabilities
Liabilities
30076000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
18000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
18000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
34000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7144000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6149000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7142000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6147000
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
7000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
301196000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
293325000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1038000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-623000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-286307000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-267534000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
13858000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25208000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42865000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55284000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12010000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9531000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34411000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26780000
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
9565000
CY2021Q3 us-gaap Cost Of Revenue
CostOfRevenue
4689000
us-gaap Cost Of Revenue
CostOfRevenue
22096000
us-gaap Cost Of Revenue
CostOfRevenue
15157000
CY2022Q3 us-gaap Gross Profit
GrossProfit
2445000
CY2021Q3 us-gaap Gross Profit
GrossProfit
4842000
us-gaap Gross Profit
GrossProfit
12315000
us-gaap Gross Profit
GrossProfit
11623000
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5008000
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3451000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
15224000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10315000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3109000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2479000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8825000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8613000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1979000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1540000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5177000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4506000
CY2022Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0
CY2021Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-29000
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-190000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
10096000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
7499000
us-gaap Operating Expenses
OperatingExpenses
29226000
us-gaap Operating Expenses
OperatingExpenses
23624000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7651000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2657000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16911000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12001000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-329000
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-36000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-552000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-172000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-424000
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-569000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1287000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1727000
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
3014000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-753000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-605000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1839000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1115000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8404000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3262000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18750000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10886000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-17000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
23000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8387000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3276000
us-gaap Net Income Loss
NetIncomeLoss
-18773000
us-gaap Net Income Loss
NetIncomeLoss
-10879000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-152000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-90000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-415000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-173000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8539000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3366000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19188000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11052000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8387000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3276000
us-gaap Net Income Loss
NetIncomeLoss
-18773000
us-gaap Net Income Loss
NetIncomeLoss
-10879000
CY2022Q3 biol Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
0
CY2021Q3 biol Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
9000
biol Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
217000
biol Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
546000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8387000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3285000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18990000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11425000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.10
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.10
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.85
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.96
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.96
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7615000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7615000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6078000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6078000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6661000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6661000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5832000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5832000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
21615000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-214000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
996000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8387000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-152000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
13858000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25208000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5635000
biol Phant Award Reclass
PhantAwardReclass
596000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1607000
us-gaap Net Income Loss
NetIncomeLoss
-18773000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-415000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
13858000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
33256000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
66000
CY2021Q3 biol Issuance Of Restricted Shares During Period Value
IssuanceOfRestrictedSharesDuringPeriodValue
164000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
192000
CY2021Q3 biol Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
10000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3276000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-90000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
30322000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
10028000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13291000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
66000
biol Issuance Of Common Stock For Settlement Of Liability
IssuanceOfCommonStockForSettlementOfLiability
510000
biol Issuance Of Restricted Shares During Period Value
IssuanceOfRestrictedSharesDuringPeriodValue
164000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2253000
biol Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
15062000
us-gaap Net Income Loss
NetIncomeLoss
-10879000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-173000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
30322000
us-gaap Profit Loss
ProfitLoss
-18773000
us-gaap Profit Loss
ProfitLoss
-10879000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
369000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
281000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
56000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-162000
biol Provision For Sales Returns
ProvisionForSalesReturns
-245000
biol Provision For Sales Returns
ProvisionForSalesReturns
0
us-gaap Inventory Write Down
InventoryWriteDown
1486000
us-gaap Inventory Write Down
InventoryWriteDown
-117000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
71000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
126000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
126000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
290000
biol Patent Litigation Mark To Market
PatentLitigationMarkToMarket
0
biol Patent Litigation Mark To Market
PatentLitigationMarkToMarket
190000
biol Issuance Of Restricted Shares
IssuanceOfRestrictedShares
0
biol Issuance Of Restricted Shares
IssuanceOfRestrictedShares
164000
us-gaap Share Based Compensation
ShareBasedCompensation
1691000
us-gaap Share Based Compensation
ShareBasedCompensation
1488000
us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
0
us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
3014000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
664000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
417000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5229000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2788000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
850000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-235000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
664000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
705000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-371000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
292000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21179000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13606000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3256000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
396000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3256000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-396000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5635000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13291000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
6000
biol Principal Payment On Loan
PrincipalPaymentOnLoan
1000000
biol Proceeds From Sale Of Common Stock Warrants
ProceedsFromSaleOfCommonStockWarrants
16560000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
25000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
66000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4635000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29886000
biol Effect Of Exchange Rate Changes
EffectOfExchangeRateChanges
-415000
biol Effect Of Exchange Rate Changes
EffectOfExchangeRateChanges
-171000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20215000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15713000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30175000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17876000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9960000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33589000
us-gaap Interest Paid Net
InterestPaidNet
1110000
us-gaap Interest Paid Net
InterestPaidNet
1328000
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
23000
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
44000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
39000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
154000
biol Cash Paid For Operating Leases
CashPaidForOperatingLeases
219000
biol Cash Paid For Operating Leases
CashPaidForOperatingLeases
185000
biol Non Cash Settlement Of Performance Award Liability
NonCashSettlementOfPerformanceAwardLiability
0
biol Non Cash Settlement Of Performance Award Liability
NonCashSettlementOfPerformanceAwardLiability
510000
biol Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation
NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation
562000
biol Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation
NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation
48000
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
217000
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
546000
CY2022Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-twenty-five
CY2022Q3 biol Working Capital
WorkingCapital
20100000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10000000.0
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4800000
CY2021Q4 biol Working Capital
WorkingCapital
35500000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30000000.0
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4200000
CY2021 us-gaap Increase Decrease In Operating Assets
IncreaseDecreaseInOperatingAssets
21200000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3300000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21200000
us-gaap Net Income Loss
NetIncomeLoss
-18800000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
6500000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of these consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect amounts reported in the consolidated financial statements and the accompanying notes. Significant estimates in these consolidated financial statements include allowances on accounts receivable, inventory, and deferred taxes, as well as estimates for accrued warranty expenses, goodwill and the ability of goodwill to be realized, revenue deferrals, effects of stock-based compensation and warrants, contingent liabilities, and the provision or benefit for income taxes. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ materially from those estimates.</span></p>
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.72
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concentration of Credit Risk, Interest Rate Risk and Foreign Currency Exchange Rate</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments which potentially expose the Company to a concentration of credit risk consist principally of cash and cash equivalents, restricted cash, and trade accounts receivable. The Company maintains its cash and cash equivalents and restricted cash with established commercial banks. At times, balances may exceed federally insured limits. To minimize the risk associated with trade accounts receivable, management performs ongoing credit evaluations of customers’ financial condition and maintains relationships with the Company’s customers that allow management to monitor current changes in business operations so the Company can respond as needed. The Company does not, generally, require customers to provide collateral before it sells them its products. However, the Company has required certain distributors to make prepayments for significant purchases of its products.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Substantially all of the Company’s revenue is denominated in U.S. dollars, including sales to international distributors. Only a small portion of its revenue and expenses is denominated in foreign currencies, principally the Euro and Indian Rupee. The Company’s foreign currency expenditures primarily consist of the cost of maintaining offices, consulting services, and employee-related costs. During the three and nine months ended September 30, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, the Company did not enter into any hedging contracts. Future fluctuations in the value of the U.S. dollar may affect the price competitiveness of the Company’s products outside the U.S.</span></p>
CY2022Q3 biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.83
biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.87
CY2021Q3 biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.88
biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.88
CY2022Q3 biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.17
biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.13
CY2021Q3 biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.12
biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.12
CY2022Q3 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
400000
CY2021Q4 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
800000
CY2022Q3 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
366000
CY2021Q4 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
835000
CY2022Q3 biol Contract With Customer Liability In Extended Warranty Contracts
ContractWithCustomerLiabilityInExtendedWarrantyContracts
1851000
CY2021Q4 biol Contract With Customer Liability In Extended Warranty Contracts
ContractWithCustomerLiabilityInExtendedWarrantyContracts
1753000
CY2022Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2217000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2588000
CY2022Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
347000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
329000
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1870000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2259000
biol Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
700000
biol Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
200000
biol Contract With Customer Liability Revenue Recognized Extended Warranty
ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty
1300000
biol Contract With Customer Liability Revenue Recognized Extended Warranty
ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty
1100000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12010000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9531000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34411000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26780000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12010000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9531000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34411000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26780000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12010000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9531000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34411000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26780000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
41000000
CY2022Q3 biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
600000
biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
1700000
CY2021Q3 biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
200000
biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
1500000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1800000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
800000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y1M6D
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
591000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
192000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1691000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1488000
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.11
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.11
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0098
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0086
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
70000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
62.01
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M6D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
18000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
22.82
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
52000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
74.95
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
50000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
77.50
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M24D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
biol Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriod
0
biol Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2022Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2021Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
66000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
66000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
42000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
42000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.49
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
12000
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
8000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
35000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
395000
CY2020Q2 biol Other Offering Expenses
OtherOfferingExpenses
700000
biol Warrants Adjusted Exercise Price
WarrantsAdjustedExercisePrice
15.00
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2600000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1000000.0
CY2021Q3 biol Temporary Equity Conversion Of Preferred Stock Into Common Stock
TemporaryEquityConversionOfPreferredStockIntoCommonStock
261
CY2022Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
6465000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
4444000
CY2022Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
2192000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1726000
CY2022Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7770000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
615000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6759000
CY2022Q3 us-gaap Inventory Net
InventoryNet
16427000
CY2021Q4 us-gaap Inventory Net
InventoryNet
12929000
CY2022Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1300000
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1000000.0
CY2022Q3 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
12167000
CY2021Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
8952000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8394000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8049000
CY2022Q3 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
3773000
CY2021Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
903000
CY2022Q3 us-gaap Land
Land
142000
CY2021Q4 us-gaap Land
Land
164000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3915000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1067000
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
100000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
100000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2021 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2022Q3 us-gaap Goodwill
Goodwill
2900000
CY2021Q4 us-gaap Goodwill
Goodwill
2900000
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3017000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3969000
CY2022Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1061000
CY2021Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
565000
CY2022Q3 us-gaap Asset Acquisition Contingent Consideration Liability
AssetAcquisitionContingentConsiderationLiability
880000
CY2021Q4 us-gaap Asset Acquisition Contingent Consideration Liability
AssetAcquisitionContingentConsiderationLiability
0
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
633000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
275000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
405000
CY2022Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
193000
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
558000
CY2022Q3 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
13000
CY2021Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
600000
CY2022Q3 biol Settlement Liability Accrual Classified Current
SettlementLiabilityAccrualClassifiedCurrent
0
CY2021Q4 biol Settlement Liability Accrual Classified Current
SettlementLiabilityAccrualClassifiedCurrent
805000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
507000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1099000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6919000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8276000
CY2022Q3 us-gaap Deferred Tax Liabilities Deferred Expense
DeferredTaxLiabilitiesDeferredExpense
200000
CY2021Q4 us-gaap Deferred Tax Liabilities Deferred Expense
DeferredTaxLiabilitiesDeferredExpense
200000
CY2022Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1233000
CY2021Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
551000
CY2021Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1086000
CY2020Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1132000
CY2022Q3 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
1255000
CY2021Q3 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
832000
us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
2715000
us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
1129000
CY2022Q3 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
1011000
CY2021Q3 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
366000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
2324000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
1244000
CY2022Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1477000
CY2021Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1017000
CY2022Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1477000
CY2021Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1017000
CY2022Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
416000
CY2021Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
472000
CY2022Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
416000
CY2021Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
472000
CY2022Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1061000
CY2021Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
545000
CY2022Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1061000
CY2021Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
545000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
562000
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
12793000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
13603000
CY2022Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12793000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
13603000
CY2022Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
400000
us-gaap Interest Expense Debt
InterestExpenseDebt
1300000
CY2021Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
600000
us-gaap Interest Expense Debt
InterestExpenseDebt
1700000
CY2022Q3 us-gaap Debt Weighted Average Interest Rate
DebtWeightedAverageInterestRate
0.1025
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2022Q3 biol Long Term Debt Maturities Repayments Of Interest Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfInterestRemainderOfFiscalYear
357000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
700000
CY2022Q3 biol Long Term Debt Maturities Repayments Of Interest In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfInterestInNextTwelveMonths
1425000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2800000
CY2022Q3 biol Long Term Debt Maturities Repayments Of Interest In Year Two
LongTermDebtMaturitiesRepaymentsOfInterestInYearTwo
1242000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
9800000
CY2022Q3 biol Long Term Debt Maturities Repayments Of Interest In Year Three
LongTermDebtMaturitiesRepaymentsOfInterestInYearThree
1895000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
0
CY2022Q3 biol Long Term Debt Maturities Repayments Of Interest In Year Four
LongTermDebtMaturitiesRepaymentsOfInterestInYearFour
9000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
150000
CY2022Q3 biol Long Term Debt Maturities Repayments Of Interest In Year After Five
LongTermDebtMaturitiesRepaymentsOfInterestInYearAfterFive
89000
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
13450000
CY2022Q3 biol Long Term Debt Maturities Repayments Of Interest
LongTermDebtMaturitiesRepaymentsOfInterest
5017000
CY2022Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
84000
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
62000
us-gaap Operating Lease Payments
OperatingLeasePayments
219000
us-gaap Operating Lease Payments
OperatingLeasePayments
185000
CY2022Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2021Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
48000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M24D
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M18D
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M24D
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M18D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.123
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.123
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.123
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.123
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
831000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
826000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
644000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
144000
CY2022Q3 biol Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
0
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2445000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
402000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2043000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
615000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1428000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2043000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1900000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2000000.0
CY2022Q3 us-gaap Payments For Rent
PaymentsForRent
300000
us-gaap Payments For Rent
PaymentsForRent
800000
CY2021Q3 us-gaap Payments For Rent
PaymentsForRent
200000
us-gaap Payments For Rent
PaymentsForRent
600000
CY2022Q3 biol Future Minimum Payments Remainder Of Fiscal Year
FutureMinimumPaymentsRemainderOfFiscalYear
205000
CY2022Q3 biol Future Minimum Payments Due In Two Years
FutureMinimumPaymentsDueInTwoYears
834000
CY2022Q3 biol Future Minimum Payments Due In Three Years
FutureMinimumPaymentsDueInThreeYears
822000
CY2022Q3 biol Future Minimum Payments Due In Four Years
FutureMinimumPaymentsDueInFourYears
584000
CY2022Q3 biol Future Minimum Payments Due Thereafter
FutureMinimumPaymentsDueThereafter
0
CY2022Q3 biol Future Minimum Payments Due
FutureMinimumPaymentsDue
2445000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
402000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2043000
CY2021Q1 biol Litigation Settlement Shares Issued
LitigationSettlementSharesIssued
20000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
600000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12010000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9531000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34411000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26780000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3915000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1067000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12010000
CY2022Q3 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1.000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9531000
CY2021Q3 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1.000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34411000
us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1.000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26780000
us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1.000
CY2022Q3 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2021Q3 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2022Q3 biol Income Tax Benefit
IncomeTaxBenefit
17000
biol Income Tax Benefit
IncomeTaxBenefit
17000
CY2022Q3 biol Income Tax Provision
IncomeTaxProvision
23000
biol Income Tax Provision
IncomeTaxProvision
23000
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.002
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.001
CY2021Q3 biol Income Tax Provision
IncomeTaxProvision
14000
biol Income Tax Provision
IncomeTaxProvision
14000
CY2021Q3 biol Income Tax Benefit
IncomeTaxBenefit
7000
biol Income Tax Benefit
IncomeTaxBenefit
7000
CY2021Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.004
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.001
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21

Files In Submission

Name View Source Status
R40.htm Edgar Link pending
0000950170-22-024532-index-headers.html Edgar Link pending
0000950170-22-024532-index.html Edgar Link pending
0000950170-22-024532.txt Edgar Link pending
0000950170-22-024532-xbrl.zip Edgar Link pending
biol-20220930.htm Edgar Link pending
biol-20220930.xsd Edgar Link pending
biol-ex2_1.htm Edgar Link pending
biol-ex31_1.htm Edgar Link pending
biol-ex31_2.htm Edgar Link pending
biol-ex32_1.htm Edgar Link pending
biol-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
biol-20220930_def.xml Edgar Link unprocessable
biol-20220930_lab.xml Edgar Link unprocessable
biol-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
biol-20220930_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
biol-20220930_cal.xml Edgar Link unprocessable